The EMBRAZE trial was designed to assess the ability to preserve lean body mass associated with tirzepatide-induced weight loss in patients with obesity (BMI of ≥30.0 kg/m 2) or overweight (BMI ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

The recently published placebo-controlled SUMMIT trial showed that tirzepatide was associated with a nearly 40% reduction (P = .026) in death from CV causes or worsening heart failure. In the new ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...